US Patent

US8383150 — Granulate formulation of pirfenidone and pharmaceutically acceptable excipients

Method of Use · Assigned to Intermune Inc · Expires 2028-05-10 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a capsule formulation of pirfenidone that can sustain desirable pharmacokinetic responses in a patient.

USPTO Abstract

A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient in need.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2361`	—
`U-2361`	—
`U-2361`	—
`U-2361`	—

Patent Metadata

Patent number: US8383150
Jurisdiction: US
Classification: Method of Use
Expires: 2028-05-10
Drug substance claim: No
Drug product claim: Yes
Assignee: Intermune Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.